4-(4-chlorobenzyloxy)phenol | 52890-66-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-(4-chlorobenzyloxy)phenol
• 英文别名: 4-(4-Chlorbenzyloxy)-phenol；4-[(4-Chlorophenyl)methoxy]phenol
• CAS: 52890-66-1
• 化学式: C₁₃H₁₁ClO₂
• mdl: MFCD11181774
• 分子量: 234.682
• InChiKey: QKXVDKRVUDDHPC-UHFFFAOYSA-N

物化性质

• 沸点：
  387.7±22.0 °C(Predicted)
• 密度：
  1.271±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-chlorobenzyloxy)phenol 在 吡啶 、 potassium carbonate 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 8.0h， 生成 (1-benzyl-5-{3-[4-(4-chlorobenzyloxy)phenoxy]propoxy}-1H-indol-3-yl)acetic acid methyl ester
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor γ/δ agonists

  摘要：

  A series of alkoxy-3-indolylacetic acid analogs has been discovered as peroxisome proliferator-activated receptor (PPAR) agonists. Structure-activity relationship study indicated that PPAR alpha/gamma/delta activities were dependent on the nature of the hydrophobic group, the attachment position of the alkoxy linker to the indole ring, and N-alkylation of indole nitrogen. Some compounds presented significant PPAR gamma/delta activity and molecular modeling suggested their putative binding modes in the ligand binding domain of PPAR gamma. Of these, compound 51 was selected for in vivo study via an evaluation of microsomal stability in mouse and human liver. Compound 51 lowered the levels of fasting blood glucose, insulin, and HbA1c without gain in body weight in db/db mice. When compound 51 was treated, hepatic triglycerides level and the size of adipocytes in white adipose tissue of db/db mice were also reduced as opposed to treatment with rosiglitazone. Taken together, compound 51 shows high potential warranting further studies in models for diabetes and related metabolic disorders and may be in use as a chemical tool for the understanding of PPAR biology. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.04.046
• 作为产物：
  描述：

  对苯二酚 、 4-氯苄溴 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 生成 4-(4-chlorobenzyloxy)phenol
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor γ/δ agonists

  摘要：

  A series of alkoxy-3-indolylacetic acid analogs has been discovered as peroxisome proliferator-activated receptor (PPAR) agonists. Structure-activity relationship study indicated that PPAR alpha/gamma/delta activities were dependent on the nature of the hydrophobic group, the attachment position of the alkoxy linker to the indole ring, and N-alkylation of indole nitrogen. Some compounds presented significant PPAR gamma/delta activity and molecular modeling suggested their putative binding modes in the ligand binding domain of PPAR gamma. Of these, compound 51 was selected for in vivo study via an evaluation of microsomal stability in mouse and human liver. Compound 51 lowered the levels of fasting blood glucose, insulin, and HbA1c without gain in body weight in db/db mice. When compound 51 was treated, hepatic triglycerides level and the size of adipocytes in white adipose tissue of db/db mice were also reduced as opposed to treatment with rosiglitazone. Taken together, compound 51 shows high potential warranting further studies in models for diabetes and related metabolic disorders and may be in use as a chemical tool for the understanding of PPAR biology. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.04.046

文献信息

• Azole Derivatives
  申请人：ZENECA LIMITED

  公开号：EP0459702A1

  公开（公告）日：1991-12-04

  The invention concerns novel, pharmaceutically useful compounds of formula I in which Q is a 5-membered heteroaryl optionally bearing 1 or 2 substituents independently selected from (1-4C)alkyl and halogeno ; R1 is hydrogen, (1-6C)alkyl, or (1-4C)alkanoyl ; R2 (when not as hereinbelow defined together with X) is hydrogen, (3-12C)cycloalkyl, (3-6C)alkenyl, phenyl(3-6C)alkenyl, tetrafluorophenyl, pentafluorophenyl, 5- or 6-membered heteroaryl, optionally substituted (1-6C)alkyl or optionally substituted phenyl ; X is oxy, thio, sulphinyl, sulphonyl or an imino group of formula -NRa- in which Ra is hydrogen, (1-6C)alkyl or together with R2 and the adjacent nitrogen atom forms a 4 to 6-membered saturated heterocyclic ring ; and A is N or CT in which T is hydrogen or (1-4C)alkyl ; or a pharmaceutically acceptable salt thereof ; processes for the manufacture of the compounds and pharmaceutical compositions containing them. The compounds are useful as adenosine antagonists. The invention further provides novel intermediates useful in the manufacture of the compounds of formula I.

  本发明涉及式 I 的新型药用化合物，其中 Q 是 5 元杂芳基，任选带有 1 或 2 个独立选自 (1-4C)烷基和卤素的取代基；R1 是氢、(1-6C)烷基或 (1-4C)alkanoyl ；R2（当不与 X 一起定义时）是氢、(3-12C)环烷基、(3-6C)烯基、苯基(3-6C)烯基、四氟苯基、五氟苯基、5 或 6 元杂芳基、任选取代的(1-6C)烷基或任选取代的苯基；X 是氧、硫代、亚砜基、磺酰基或式 -NRa- 的亚氨基，其中 Ra 是氢、(1-6C)烷基或与 R2 和邻近的氮原子一起形成 4 至 6 元饱和杂环；以及 A 是 N 或 CT，其中 T 是氢或 (1-4C)烷基；或其药学上可接受的盐；化合物的制造工艺和含有这些化合物的药物组合物。这些化合物可用作腺苷拮抗剂。本发明进一步提供了用于制造式 I 化合物的新型中间体。
• Thiele; Ahmed; Jahn, Arzneimittel-Forschung/Drug Research, 1979, vol. 29, # 5, p. 711 - 720
  作者：Thiele、Ahmed、Jahn、Adrian

  DOI：——

  日期：——
• PROCESS FOR PRODUCTION OF ALCOHOL COMPOUND
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP2036878B1

  公开（公告）日：2012-08-22
• US5270311A
  申请人：——

  公开号：US5270311A

  公开（公告）日：1993-12-14
• US5356894A
  申请人：——

  公开号：US5356894A

  公开（公告）日：1994-10-18